Home Press Releases Global Radiodermatitis Market Size Worth $649.58 Million By 2032 | CAGR: 4.1%

Global Radiodermatitis Market Size Worth $649.58 Million By 2032 | CAGR: 4.1%

The global radiodermatitis market size is expected to reach USD 649.58 million by 2032, according to a new study by Polaris Market Research. The report “Global Radiodermatitis Market Share, Size, Trends, Industry Analysis Report, By Product (Topical, Oral, and Dressings); By Distribution Channel; By Region; Segment Forecast, 2023-2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

 

Several governing and non-governing bodies are taking constructive steps to promote information regarding accessible radiodermatitis therapy and management items. This is accelerating market expansion along with the increased public and private investments in current research and development (R&D) projects in the life sciences sector. The National Cancer Institute (NCI) monitors how money is spent across diffetent cancer types, cancer-related disorders, and NCI research procedures. The NCI had USD 5.9 Bn in funds available in FY 2018 (including USD 300 Mn in the CURES Act funding), which was up 5%, or USD 284 Mn, from the previous fiscal year. Non-competing grants were provided at 100% of the agreed level under the NCI RPG expense policies.

 

Furthermore, these groups also disseminate advice on how to treat the condition successfully, which is projected to increase the potential for growth in the extended run. For instance, the BC Cancer Agency of the Provincial Health Services Authority has released data on radiodermatitis treatment. This is anticipated to advance understanding of evaluation and treatment techniques as well as general skincare guidance, enhancing prospective growth. As more clinical studies are carried out to evaluate the efficacy of a range of radiodermatitis therapy items for treatment, it is anticipated that the product pipeline will expand and the market will have lucrative growth potential.

 

Have Questions? Request a sample or make an Inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/radiodermatitis-market/request-for-sample

 

Furthermore, to diversify their product offerings and acquire a competitive advantage, the major firms are concentrating on creating inventive product varieties. In December 2020, It has been announced that Sonoma Pharmaceuticals & Crown Laboratories have reached a deal for the exclusive selliong license & to promote medicine for the OTC dermatological market in the U.S. Crown intends to market Sonoma’s Microcyn technology dermal spray and gels that target itch and discomfort under the name Sarna, the #1 Dermatologist approved Anti-Itch Brand, with a distinctive selection of formulations to fast cure itching & skin irritations. Therefore, these collaborations for the launches of dermatologist products are bolstering the growth of radiodermatitis over the forecast period.

 

Global Radiodermatitis Market Report Highlights

  • The online segment grown at a high CAGR over the study period due to increased patient convenience since it offers goods home delivery. Additionally, patients can receive rebates on radiodermatitis medicines through online pharmacies
  • The retail segment garnered largest of the global revenue share due to the availability of economical product alternatives, neighborhood pharmacies, and the availability of generic versions of medications
  • North America is expected to grow at a high CAGR over the projected period due to the incorporation of radiodermatitis products in healthcare reimbursement policies, an increase in the number of cancer patients
  • The global players in the market include 3M Company, Acelity L.P., Bayer, Convatec Group, Friulia S.p.A. Glaxosmithkline, Helsinn Healthcare, Kannalife, Molnlycke Health Care, Mylan, Rebound Therapeutics, Smith & Nephew, and Stratpharma.

 

Polaris Market Research has segmented the global radiodermatitis market report based on distribution channel, product, and region:

 

Radiodermatitis, Product Outlook (Revenue – USD Million, 2019 – 2032)

  • Topical
    • Corticosteroids
    • Hydrophilic creams
    • Antibiotics
    • Others
  • Oral
  • Dressings
    • Hydrogel & Hydrocolloid dressings
    • No Sting Barrier Film
    • Honey-Impregnated Gauze
    • Silicone Coated Dressings
    • Others

Radiodermatitis, Distribution Channel Outlook (Revenue – USD Million, 2019 – 2032)

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online

Radiodermatitis, Regional Outlook (Revenue – USD Million, 2019 – 2032)

  • North America
    • U.S
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Russia
    • Netherlands
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Indonesia
    • Malaysia
  • Latin America
    • Argentina
    • Brazil
    • Mexico
  • Middle East & Africa
    • UAE
    • Saudi Arabia
    • Israel
    • South Africa

License and Pricing

Buy Now

Purchase Report Sections

  • Regional analysis
  • Segmentation analysis
  • Industry outlook
  • Competitive landscape
Request for Discount Pricing

Request For Customization

Please specify your research requirement and get customized report


Regional AnalysisSegmentation AnalysisIndustry OutlookCompetitive Analysis
By using this form you agree with the storage and handling of your data by this website.

Speak to Analyst

By using this form you agree with the storage and handling of your data by this website.